Changes of Humoral Immunity Response in SARS-CoV-2 **Convalescent Patients over 8 months**

Jie Hu,1,# Hai-jun Deng,1 Bei-zhong Liu,2 Kai Wang,1,* Ni Pai Peng. 1,# Tang, 1,* Ai-long Huang, 1,*

Auhtor Notes:

[#] Pai Peng and Jie Hu shared co-first authorship positions.

*Ai-long Huang, Ni Tang and Kai Wang have equal contributions in this work.

Author Affiliations:

¹Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education). Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.

² Yong-Chuan Hospital, Chongqing Medical University, Chongqing, China

Corresponding author: Ai-long Huang, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. (Tel: 86-23-68486780; Email: ahuang@cqmu.edu.cn)

Abstract

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

Many countries around the world have all seen a sharp rise in COVID-19 cases as the second wave since the beginning of October 2020. Decline of antibodies response to severe acute respiratory syndrome coronavirus (SARS-CoV-2) that was reported exclusively in the early month increases the risk of reinfection for convalescent individuals. There is a current need to follow the maintenance of special antibodies against SARS-CoV-2. Here, we reported changes of antibodies against SARS-CoV-2 in convalescent patients over 8 months. Antibodies of all 20 participants targeting SARS-CoV-2 spike receptor binding-domain (RBD) had decreased from a mean OD₄₅₀ value 1.78 to 0.38 over 8 months. The neutralizing antibody (NAb) titers decreased from the mean ID50 value 836 to 170. The NAb titers were significantly correlated with IgG level during 8 months (P<0.001). Furthermore, while RBD-specific IgG existence of 25% (5/20) convalescent plasma was undetectable, the NAb titers of 15% (3/20) convalescent plasma decreased below the threshold. In addition, compared to wild-type SARS-CoV-2 (S-D614), lower titers of neutralizing antibodies against its G614 variant were shown at 8 months after symptom onset. This study has important

implications when considering antibody protection against SARS-CoV-2 reinfection.

Methods

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

Twenty patients who had recovered from COVID-19 were included in our cohort (see Table). Blood samples were obtained in February and October with correspond to a median of 25 days (range 5 to 33 days) and 230 days (range 221 to 248 days) after symptom onset (Figure A). Enzyme-linked immunosorbent assay (ELISA) was performed to evaluate the presence of anti-SARS-CoV-2 spike (S) receptor-binding domain (RBD) IgG over 8 months. A preliminary positive cutoff was set with the mean value of negative controls above 3 standard deviation1. The neutralizing antibodies (NAbs) were measured by SARS-CoV-2 wild-type (S-D614) and S-G614 mutant pseudovirus-based assays in 293T-ACE2 cells. The inhibitory dose (ID₅₀) was calculated as the titers of NAbs. **Results** Antibodies of all 20 participants targeting SARS-CoV-2 spike RBD had decreased from a mean OD₄₅₀ value 1.78 (range 0.55 to 2.72) to 0.38 (range 0.15 to 1.01) over 8 months. When OD₄₅₀ value was less than 0.26, the specimen was considered seronegative. At the follow-up time point 2 (in October), IgG level of 5 participants (25%) became negative (Figure B). A similar decline had been observed in the pseudovirus neutralization assay. The NAb titers decreased from the mean ID₅₀ value 836.55 (range 263-1160) to 170.30 (range 33 to 365). Among them, NAb titers of 3 participants (15%) were lower than the threshold at 8 months after symptom onset (Figure C). Moreover, the NAb titers were significantly correlated with IgG levels (Figure D).

Cross-protective role of neutralizing antibodies at 8 months after symptom onset were

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

immunity.

evaluated in SARS-CoV-2 S-G614, which has been the dominant form of SARS-CoV-2 worldwide. NAb titers of 5 participants (25%) decreased below the threshold against S-G614 mutant pseudovirus. Moreover, there was a statistically significant difference in neutralizing efficacy of convalescent plasma to SARS-CoV-2 S-D614 and S-G614 mutant pseudovirus (Figure E). **Discussion** In this study, we reported changes of humoral immunity response in SARS-CoV-2 convalescent patients over 8 months. In agreement with previous follow-up studies within a shorter time, decline of both IgG and NAb level were observed¹⁻³. Furthermore, better significant correlation between IgG and NAb level in February than in October indicates that anamnestic immune response and other protective immunity should be evaluated in the context of low-level neutralizing antibodies⁴. Facing the challenge of the second wave of SARS-CoV-2, the risk of reinfection by the currently dominant SARS-CoV-2 S-G614 variant is worthy to be considered, especially for Chinese convalescent patients infected by wild-type SARS-CoV-2. The weaker neutralizing activity to S-G614 mutant pseudovirus has been shown. In two samples, neutralizing antibody titers even quickly decrease from 1:99 or 1:122 to near the limit of detection. That might be a warning about the possible loss of protective ability of convalescent plasma with lower titers to SARS-CoV-2 S-G614 variant, like the reinfection case found in Hongkong⁵. Therefore, more data about the longevity of humoral immunity are needed to evaluate the effectiveness of herd

- 62 According to the current data, evaluation of the duration of humoral immunity response is limit.
- 63 Meanwhile, there are limitations to our study on the lack of correlation analysis between
- 64 clinical characteristics and specific antibody levels due to the small sample size, as well as on
- 65 the lack of data to evaluate anamnestic immune response.

Table. Clinical characteristics of 20 convalescent individuals in the cohort*.

	D. C. A
Characteristics	Patients
	(N=20)
Age (median, IQR)	51.5
	(44.8-65.0)
Sex (Male/Female)	
Male	11 (55.0%)
Female	9 (45.0%)
Exposure	
From Wuhan	3 (15.0%)
Close contacts	17 (85.0%)
Severity	
Non-severe	18 (90.0%)
Severe	2 (10.0%)
Hospitalization (days)	25 (18-28)
Comorbidities	
Hypertension	4 (20.0%)
Cardiovascular disease	2 (10.0%)
Diabetes	3 (15.0%)
COPD	1 (5.0%)
Chronic liver disease	1 (5.0%)
Signs and symptoms	
Fever	7 (35.0%)
Fatigue	1 (5.0%)
Dry cough	6 (30.0%)
Inappetence	1 (5.0%)
Myalgia	1 (5.0%)
Dypnea	2 (10.0%)
Expectoration	4 (20.0%)
Pharyngalgia	1 (5.0%)
Dizziness	1 (5.0%)
Vomiting	1 (5.0%)
Chill	2 (10.0%)
Rhinorrhea	1 (5.0%)
Chest stuffiness	1 (5.0%)
	(51570)

⁶⁸ *Blood samples were obtained at Yongchuan Hospital of Chongqing Medical University,

66

67

⁶⁹ Chongqing, China

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.




Figure. Maintenance of humoral response to SARS-CoV-2 in convalescent patients over 8 months. (**A**) Blood samples were collected in February and October. Enzyme-linked immunosorbent assay (ELISA) (**B**) and pseudovirus-based neutralization assay (**C**) were performed to detect IgG levels and neutralizing antibody (NAb) titers against SARS-CoV-2. The thresholds of detection were 0.26 of OD₄₅₀ value and 1:40 of ID₅₀, separately. (**D**) Correlation of IgG and NAb level. (**E**) Different neutralizing activity of convalescent plasma between SARS-CoV-2 S-D614 and S-G614 mutant at 8 months after symptom onset.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

References

78

- 79 1. Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological Assays
- 80 Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity.
- 81 Immunity. 2020.
- 82 2. Patel MM, Thornburg NJ, Stubblefield WB, et al. Change in antibodies to SARS-CoV-2 over
- 83 60 days among health care personnel in Nashville, Tennessee. JAMA. 2020.
- 84 3. Wang K, Long Q-X, Deng H-J, et al. Longitudinal dynamics of the neutralizing antibody
- response to SARS-CoV-2 infection. Clinical Infectious Diseases. 2020.
- 4. Chen Y, Zuiani, A., Fischinger, S., Mullur, J., Atyeo, C., Travers, M., Lelis, F.J.N. P, K.M.,
- 87 Martin, H., Tong, P., Gautam, A., Habibi, S., Bensko, J., Gakpo, D., Feldman, J., Hauser BM,
- 88 Caradonna, T.M., Cai, Y., Burke, J.S., Lin, J., Lederer, J.A., Lam, E.C., Lavine, C.L., Seaman
- MS, Chen, B., Schmidt, A.G., Balazs, A.B., Lauffenburger, D.A., Alter, G., Wesemann, D.R.,
- 90 Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell. 2020.
- 91 5. To KK-W, Hung IF-N, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct
- 92 SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clinical infectious
- 93 diseases. 2020.

94

- 95 Author Contributions: PaiPeng and Jie Hu had full access to all of the data in the study and
- take responsibility for the integrity of the data and the accuracy of the data analysis. 96
- 97 Concept and design: Ai-long Huang, Ni Tang, Kai Wang, Pai Peng, Jie Hu.
- 98 Acquisition, analysis, or interpretation of data: All authors.
- 99 Drafting of the manuscript: Pai Peng.
- 100 Critical revision of the manuscript for important intellectual content: All authors.
- 101 Statistical analysis: Hai-jun Deng.
- 102 Administrative, technical, or material support: Ai-long Huang, Ni Tang, Kai Wang, Pai Peng, Jie
- Hu. 103
- 104 Supervision: Ai-long Huang, Ni Tang, Kai Wang.